3549: Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC) Debra L. Richardson, Minal A. Barve, James F. Strauss, Susanna V. Ulahannan, Kathleen N. Moore, Erika P. Hamilton, Melissa L. Johnson, Kyriakos P. Papadopoulos, Corrine Zarwan, Charles K. Anderson, Joseph Buscema, Deborah B. Doroshow, William J. Edenfield, ...